Novavax, Inc.
NVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.02 | 0.02 | -0.03 |
| FCF Yield | -8.20% | -159.77% | -63.32% | 2.49% |
| EV / EBITDA | -8.55 | -0.30 | -0.03 | -5.70 |
| Quality | ||||
| ROIC | -60.27% | -338.23% | -427.51% | -532.10% |
| Gross Margin | 70.28% | 38.21% | 43.55% | 100.00% |
| Cash Conversion Ratio | 0.47 | 1.31 | 0.63 | -0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | -24.72% | 41.21% | 314.90% | 119.58% |
| Free Cash Flow Growth | 87.02% | -51.85% | -291.71% | 373.21% |
| Safety | ||||
| Net Debt / EBITDA | 2.77 | 0.70 | 1.30 | 0.63 |
| Interest Coverage | -12.40 | -39.30 | -32.43 | -79.83 |
| Efficiency | ||||
| Inventory Turnover | 23.17 | 8.24 | 24.61 | 0.00 |
| Cash Conversion Cycle | -1.17 | 98.47 | -53.92 | 840.53 |